Formoterol Fumarate (Oxis)

An ADRENERGIC BETA-2 RECEPTOR AGONIST with a prolonged duration of action. It is used to manage ASTHMA and in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Also Known As:

Oxis; 3-Formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate; Arformoterol; BD 40A; Eformoterol; Foradil; Formoterol; Formoterol Fumarate, ((R*,R*)-(+-))-isomer; Formoterol, ((R*,R*)-(+-))-isomer

Networked: 1591 relevant articles (301 outcomes, 638 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Amino Alcohols: 20
    - Ethanolamines: 16
      - Formoterol Fumarate: 1591
        Formoterol Fumarate Drug Combination Budesonide: 88
        fluticasone-formoterol: 30
        budesonide-glycopyrrolate-formoterol fumarate drug combination: 23
        Formoterol Fumarate Drug Combination Mometasone Furoate: 2
- Alcohols: 595
  - Amino Alcohols: 20
    - Ethanolamines: 16
      - Formoterol Fumarate: 1591
        Formoterol Fumarate Drug Combination Budesonide: 88
        fluticasone-formoterol: 30
        budesonide-glycopyrrolate-formoterol fumarate drug combination: 23
        Formoterol Fumarate Drug Combination Mometasone Furoate: 2

Experts

1.	Singh, Dave: 38 articles (04/2022 - 01/2011)
2.	Papi, Alberto: 33 articles (04/2022 - 02/2008)
3.	Reisner, Colin: 29 articles (01/2021 - 09/2014)
4.	O'Byrne, Paul M: 27 articles (01/2022 - 01/2004)
5.	Reddel, Helen K: 27 articles (01/2022 - 03/2010)
6.	Cazzola, Mario: 27 articles (04/2021 - 01/2003)
7.	Tashkin, Donald P: 26 articles (01/2020 - 01/2004)
8.	Beasley, Richard: 24 articles (02/2022 - 03/2004)
9.	Darken, Patrick: 23 articles (08/2021 - 09/2014)
10.	Donohue, James F: 23 articles (01/2021 - 04/2006)

Related Diseases

1.	Asthma (Bronchial Asthma) 07/01/2006 - "Significant clinical data support the use of formoterol in combination with ICSs for the treatment of asthma, with studies demonstrating improved pulmonary function and symptom scores and decreased need for maintenance ICSs and short-acting beta2-adrenergic agonists (SABAs) as relief medication. " 10/01/1990 - "We conclude that formoterol in a dose of 12 micrograms via MDI confers good protection against nocturnal asthma; this was only insufficient for some patients with severe asthma, and further studies with higher dosages in these patients are clearly indicated." 10/01/2004 - "Asthma-related QOL (total score) was significantly improved with formoterol treatment compared with placebo (P < 0.015). " 05/01/2002 - "Formoterol treatment resulted in significantly greater and earlier improvements compared with the other two groups in several criteria: PEF variability (17.9 +/- 2.5; 21.9 +/- 3.2; 23.7 +/- 3.3; P < 0.001); asthma symptom score (daytime) (1.6 +/- 0.5; 1 +/- 0.5; 2.0 +/- 0,5; P < 0.05); asthma symptom score (night-time) (1.2 +/- 0.4; 2.2 +/- 0.5; 16 +/- 0.6; P < 0001); and supplement alter butalin use (1.2 +/- 0.3; 1.8 +/- 0.5; 1.7 +/- 0.5; P < 0.05). " 11/01/1992 - "We conclude that prolonged use of formoterol fumarate twice daily results in sustained improvement in symptoms and flow rates in asthma with no evidence of tachyphylaxis."
2.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2008 - "There are limited clinical trial data that demonstrate that arformoterol produces significant improvement in lung function in COPD; however, many of the subjects involved had marked baseline airway reversibility. " 01/01/2009 - "These studies demonstrated that treatment with arformoterol significantly improved various lung function parameters, overall clinical status and ability to function, as well as significantly reduced COPD exacerbations and use of rescue medication. " 02/01/2008 - "In these trials, COPD subjects administered nebulized arformoterol demonstrated significant and sustained improvement in lung function over 12 weeks." 05/01/2003 - "A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD." 04/01/2010 - "Clinical trials in COPD patients have demonstrated that arformoterol is as effective in improving lung function and symptoms as other available long-acting inhaled beta(2)-agonists. "
3.	Inflammation (Inflammations) 01/01/2022 - "TNFα-induced transcripts modulated by formoterol were annotated with enriched gene ontology terms related to inflammation and proliferation, notably "GO:0070374~positive regulation of ERK1 and ERK2 cascade," which is an apparent β-arrestin-2 target. " 01/01/2020 - "The immunomodulatory potential of formoterol to influence the CNS response to systemic inflammation was also assessed. " 06/22/2012 - "Lung epithelial-C/EBPβ contributes to LPS-induced inflammation and its suppression by formoterol." 08/01/2001 - "There was no difference in the profile of exacerbations in any groups, indicating formoterol does not mask any signs of inflammation. " 09/01/1997 - "These results suggest that the anti-inflammatory properties of formoterol in inflamed airways may contribute to the beneficial effects in the treatment of airway inflammation."
4.	Dyspnea (Shortness of Breath) 01/01/2016 - "Aclidinium/formoterol improved dyspnea, early-morning symptom severity, and limitation of activities versus placebo in both less and more symptomatic patients (P<0.001). " 01/01/2016 - "These post hoc analyses evaluated the efficacy of aclidinium/formoterol versus placebo or monotherapies in patients defined as less/more symptomatic by a) Evaluating Respiratory Symptoms (E-RS™) score ≥10/<10 and b) Baseline Dyspnea Index score <7/≥7. " 11/01/2023 - "There was an improvement in transition dyspnea index focal score at Week 24 for aclidinium/formoterol vs placebo (LS mean 0.8; 95% CI 0.2, 1.3; p = 0.005) but not for aclidinium vs placebo (LS mean 0.4; 95% CI -0.1, 1.0; p = 0.132). " 01/01/2016 - "The fixed-dose combination of aclidinium 400 μg/formoterol 12 μg has shown in randomized controlled trials fast and sustained bronchodilation that was greater than either monotherapy and provided clinically significant improvements in dyspnea and health status compared with placebo, also reducing the use of rescue medications. " 01/01/2016 - "Furthermore, patients with a low symptom burden achieved benefits with aclidinium/formoterol versus monotherapies in postdose FEV1, dyspnea, and early-morning symptoms."
5.	Exercise-Induced Asthma (Asthma, Exercise Induced) 01/01/2000 - "Although formoterol, a new long-acting beta(2)-adrenergic agonist, has a rapid bronchodilating action, no studies have previously examined whether it can provide equally rapid protection against exercise-induced bronchospasm (EIB). " 10/01/2002 - "Formoterol provides long-lasting protection against exercise-induced bronchospasm." 09/01/1997 - "Sixteen children aged 8-15 yrs with exercise-induced asthma (EIA) took part in the main trial comparing the protective effect of 12 micrograms formoterol inhaled at 60 and 120 L.min-1. " 07/01/1991 - "Noncomparative studies indicate formoterol also provides effective prophylaxis of exercise-induced asthma. " 01/01/2001 - "Formoterol is a highly effective therapeutic agent in the prevention of exercise-induced bronchospasm (EIB). "

Related Drugs and Biologics

1.	Budesonide (Pulmicort)
2.	Salmeterol Xinafoate (Serevent)
3.	Adrenal Cortex Hormones (Corticosteroids)
4.	Tiotropium Bromide (Spiriva)
5.	Albuterol (Salbutamol)
6.	Fluticasone (Cutivate)
7.	Glycopyrrolate (Glycopyrronium Bromide)
8.	Beclomethasone (Beclometasone)
9.	Bronchodilator Agents (Bronchodilators)
10.	Formoterol Fumarate Drug Combination Budesonide

Related Therapies and Procedures

1.	Therapeutics
2.	Nebulizers and Vaporizers (Inhaler)
3.	Metered Dose Inhalers (Metered Dose Inhaler)
4.	Dry Powder Inhalers
5.	Aftercare (After-Treatment)